Aims: Ductal carcinoma in situ (DCIS) is recognised by the World Health Organisation (WHO) Classification of Tumours (WCT) as a non‐invasive neoplastic epithelial proliferation confined to the mammary ducts and lobules. This report categorises the references cited in the DCIS chapter of the 5th edition of the WCT (Breast Tumours) according to prevailing evidence levels for evidence‐based medicine and the Hierarchy of Evidence for Tumour Pathology (HETP), identifying potential gaps that can inform subsequent editions of the WCT for this tumour. Methods and results: We included all citations from the DCIS chapter of the WCT (Breast Tumours, 5th edition). Each citation was appraised according to its study design and evidence level. We developed our map of cited evidence, which is a graphical matrix of tumour type (column) and tumour descriptors (rows). Spheres were used to represent the evidence, with size and colour corresponding to their number and evidence level respectively. Thirty‐six publications were retrieved. The cited literature in the DCIS chapter comprised mainly case series and were regarded as low‐level. We found an unequal distribution of citations among tumour descriptors. ‘Pathogenesis’ and ‘prognosis and prediction’ contained the most references, while ‘clinical features’, ‘aetiology’ and ‘diagnostic molecular pathology’ had only a single citation each. ‘Prognosis and prediction’ had the greatest proportion of moderate‐ and high‐levels of evidence. Conclusion: Our findings align with the disposition for observational studies inherent in the field of pathology. Our map is a springboard for future efforts in mapping all available evidence on DCIS, potentially augmenting the editorial process and future editions of WCTs.
Journal article
Histopathology
Wiley
18/07/2024
tumour classification, breast tumours, ductal carcinoma in situ, evidence mapping